Long-term effects of beta-blocker use on lung function in japanese patients with chronic obstructive pulmonary disease

Naohiro Oda, Nobuaki Miyahara, Hirohisa Ichikawa, Yasushi Tanimoto, Kazuhiro Kajimoto, Makoto Sakugawa, Haruyuki Kawai, Akihiko Taniguchi, Daisuke Morichika, Mitsune Tanimoto, Arihiko Kanehiro, Katsuyuki Kiura

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Some recent studies have suggested that beta-blocker use in patients with chronic obstructive pulmonary disease (COPD) is associated with a reduction in the frequency of acute exacerbations. However, the long-term effects of beta-blocker use on lung function of COPD patients have hardly been evaluated. Patients and methods: We retrospectively reviewed 31 Japanese COPD patients taking beta-blockers for >1 year and 72 patients not taking them. The association between beta-blocker use and the annual change in forced expiratory volume in 1 second (FEV1) was assessed. Results: At baseline, patient demographic characteristics were as follows: 97 males (mean age 67.0±8.2 years); 32 current smokers; and Global Initiative for Chronic Obstructive Lung disease (GOLD) stages I: n=26, II: n=52, III: n=19, and IV: n=6. Patients taking beta-blockers exhibited a significantly lower forced vital capacity (FVC), FEV1, and %FVC, and a more advanced GOLD stage. The mean duration of beta-blocker administration was 2.8±1.7 years. There were no differences in the annual change in FEV1 between patients who did and did not use beta-blockers (-7.6±93.5 mL/year vs -4.7±118.9 mL/year, P=0.671). After controlling for relevant confounders in multivariate analyses, it was found that beta-blocker use was not significantly associated with the annual decline in FEV1 (β=-0.019; 95% confidence interval: -0.073 to 0.036; P=0.503). Conclusion: Long-term beta-blocker use in Japanese COPD patients might not affect the FEV1, one of the most important parameters of lung function in COPD patients.

Original languageEnglish
Pages (from-to)1119-1124
Number of pages6
JournalInternational Journal of COPD
Volume12
DOIs
Publication statusPublished - Apr 10 2017

Fingerprint

Chronic Obstructive Pulmonary Disease
Lung
Forced Expiratory Volume
Vital Capacity
Multivariate Analysis
Demography
Confidence Intervals

Keywords

  • Beta-blocker
  • Chronic obstructive pulmonary disease
  • Forced expiratory volume in 1 second
  • Long-term
  • Lung function
  • Spirometry

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

Long-term effects of beta-blocker use on lung function in japanese patients with chronic obstructive pulmonary disease. / Oda, Naohiro; Miyahara, Nobuaki; Ichikawa, Hirohisa; Tanimoto, Yasushi; Kajimoto, Kazuhiro; Sakugawa, Makoto; Kawai, Haruyuki; Taniguchi, Akihiko; Morichika, Daisuke; Tanimoto, Mitsune; Kanehiro, Arihiko; Kiura, Katsuyuki.

In: International Journal of COPD, Vol. 12, 10.04.2017, p. 1119-1124.

Research output: Contribution to journalArticle

Oda, Naohiro ; Miyahara, Nobuaki ; Ichikawa, Hirohisa ; Tanimoto, Yasushi ; Kajimoto, Kazuhiro ; Sakugawa, Makoto ; Kawai, Haruyuki ; Taniguchi, Akihiko ; Morichika, Daisuke ; Tanimoto, Mitsune ; Kanehiro, Arihiko ; Kiura, Katsuyuki. / Long-term effects of beta-blocker use on lung function in japanese patients with chronic obstructive pulmonary disease. In: International Journal of COPD. 2017 ; Vol. 12. pp. 1119-1124.
@article{eb834396cedd46a9b87b3572c93cb446,
title = "Long-term effects of beta-blocker use on lung function in japanese patients with chronic obstructive pulmonary disease",
abstract = "Background: Some recent studies have suggested that beta-blocker use in patients with chronic obstructive pulmonary disease (COPD) is associated with a reduction in the frequency of acute exacerbations. However, the long-term effects of beta-blocker use on lung function of COPD patients have hardly been evaluated. Patients and methods: We retrospectively reviewed 31 Japanese COPD patients taking beta-blockers for >1 year and 72 patients not taking them. The association between beta-blocker use and the annual change in forced expiratory volume in 1 second (FEV1) was assessed. Results: At baseline, patient demographic characteristics were as follows: 97 males (mean age 67.0±8.2 years); 32 current smokers; and Global Initiative for Chronic Obstructive Lung disease (GOLD) stages I: n=26, II: n=52, III: n=19, and IV: n=6. Patients taking beta-blockers exhibited a significantly lower forced vital capacity (FVC), FEV1, and {\%}FVC, and a more advanced GOLD stage. The mean duration of beta-blocker administration was 2.8±1.7 years. There were no differences in the annual change in FEV1 between patients who did and did not use beta-blockers (-7.6±93.5 mL/year vs -4.7±118.9 mL/year, P=0.671). After controlling for relevant confounders in multivariate analyses, it was found that beta-blocker use was not significantly associated with the annual decline in FEV1 (β=-0.019; 95{\%} confidence interval: -0.073 to 0.036; P=0.503). Conclusion: Long-term beta-blocker use in Japanese COPD patients might not affect the FEV1, one of the most important parameters of lung function in COPD patients.",
keywords = "Beta-blocker, Chronic obstructive pulmonary disease, Forced expiratory volume in 1 second, Long-term, Lung function, Spirometry",
author = "Naohiro Oda and Nobuaki Miyahara and Hirohisa Ichikawa and Yasushi Tanimoto and Kazuhiro Kajimoto and Makoto Sakugawa and Haruyuki Kawai and Akihiko Taniguchi and Daisuke Morichika and Mitsune Tanimoto and Arihiko Kanehiro and Katsuyuki Kiura",
year = "2017",
month = "4",
day = "10",
doi = "10.2147/COPD.S133071",
language = "English",
volume = "12",
pages = "1119--1124",
journal = "International Journal of COPD",
issn = "1176-9106",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Long-term effects of beta-blocker use on lung function in japanese patients with chronic obstructive pulmonary disease

AU - Oda, Naohiro

AU - Miyahara, Nobuaki

AU - Ichikawa, Hirohisa

AU - Tanimoto, Yasushi

AU - Kajimoto, Kazuhiro

AU - Sakugawa, Makoto

AU - Kawai, Haruyuki

AU - Taniguchi, Akihiko

AU - Morichika, Daisuke

AU - Tanimoto, Mitsune

AU - Kanehiro, Arihiko

AU - Kiura, Katsuyuki

PY - 2017/4/10

Y1 - 2017/4/10

N2 - Background: Some recent studies have suggested that beta-blocker use in patients with chronic obstructive pulmonary disease (COPD) is associated with a reduction in the frequency of acute exacerbations. However, the long-term effects of beta-blocker use on lung function of COPD patients have hardly been evaluated. Patients and methods: We retrospectively reviewed 31 Japanese COPD patients taking beta-blockers for >1 year and 72 patients not taking them. The association between beta-blocker use and the annual change in forced expiratory volume in 1 second (FEV1) was assessed. Results: At baseline, patient demographic characteristics were as follows: 97 males (mean age 67.0±8.2 years); 32 current smokers; and Global Initiative for Chronic Obstructive Lung disease (GOLD) stages I: n=26, II: n=52, III: n=19, and IV: n=6. Patients taking beta-blockers exhibited a significantly lower forced vital capacity (FVC), FEV1, and %FVC, and a more advanced GOLD stage. The mean duration of beta-blocker administration was 2.8±1.7 years. There were no differences in the annual change in FEV1 between patients who did and did not use beta-blockers (-7.6±93.5 mL/year vs -4.7±118.9 mL/year, P=0.671). After controlling for relevant confounders in multivariate analyses, it was found that beta-blocker use was not significantly associated with the annual decline in FEV1 (β=-0.019; 95% confidence interval: -0.073 to 0.036; P=0.503). Conclusion: Long-term beta-blocker use in Japanese COPD patients might not affect the FEV1, one of the most important parameters of lung function in COPD patients.

AB - Background: Some recent studies have suggested that beta-blocker use in patients with chronic obstructive pulmonary disease (COPD) is associated with a reduction in the frequency of acute exacerbations. However, the long-term effects of beta-blocker use on lung function of COPD patients have hardly been evaluated. Patients and methods: We retrospectively reviewed 31 Japanese COPD patients taking beta-blockers for >1 year and 72 patients not taking them. The association between beta-blocker use and the annual change in forced expiratory volume in 1 second (FEV1) was assessed. Results: At baseline, patient demographic characteristics were as follows: 97 males (mean age 67.0±8.2 years); 32 current smokers; and Global Initiative for Chronic Obstructive Lung disease (GOLD) stages I: n=26, II: n=52, III: n=19, and IV: n=6. Patients taking beta-blockers exhibited a significantly lower forced vital capacity (FVC), FEV1, and %FVC, and a more advanced GOLD stage. The mean duration of beta-blocker administration was 2.8±1.7 years. There were no differences in the annual change in FEV1 between patients who did and did not use beta-blockers (-7.6±93.5 mL/year vs -4.7±118.9 mL/year, P=0.671). After controlling for relevant confounders in multivariate analyses, it was found that beta-blocker use was not significantly associated with the annual decline in FEV1 (β=-0.019; 95% confidence interval: -0.073 to 0.036; P=0.503). Conclusion: Long-term beta-blocker use in Japanese COPD patients might not affect the FEV1, one of the most important parameters of lung function in COPD patients.

KW - Beta-blocker

KW - Chronic obstructive pulmonary disease

KW - Forced expiratory volume in 1 second

KW - Long-term

KW - Lung function

KW - Spirometry

UR - http://www.scopus.com/inward/record.url?scp=85018513212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018513212&partnerID=8YFLogxK

U2 - 10.2147/COPD.S133071

DO - 10.2147/COPD.S133071

M3 - Article

C2 - 28435245

AN - SCOPUS:85018513212

VL - 12

SP - 1119

EP - 1124

JO - International Journal of COPD

JF - International Journal of COPD

SN - 1176-9106

ER -